Sign inStart free

Health Care · Biological Products, (No Diagnostic Substances)

INMB Inmune Bio, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 171175471 filings
Russell 2000
Follow INMB for alertsAsk AI about INMB

INMB at a glance

Inmune Bio, Inc. (INMB, SEC CIK 1711754) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 14, 2026 and Form 4 insider filings as recently as September 23, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Inmune Bio, Inc. (INMB) reported revenue of $50,000 (up 257.1% from FY2024) and a net loss of $45.9 million. Diluted EPS was -$1.86.
  • As of June 30, 2026, 20 institutional investment managers tracked by SignalX reported holding Inmune Bio, Inc. (INMB) shares worth $4.3 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$50K
+257.1% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
20 funds
$4.3M · +2 vs prior quarter
Latest 8-K
Sep 14, 2026
Item 5.02 · Item 8.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Jun 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $0 vs $0 YoY
  • Net loss $1.3M vs $24.5M; operating loss $1.5M vs $24.6M
  • R&D benefit $0.8M vs $5.8M expense; CORDStrom/INKmune costs $2.5M vs $1.1M
  • Cash $18.4M at June 30 vs $24.8M at December 31; operating cash use $6.6M vs $14.2M YoY
  • MAA targeted UK by Q3 or early Q4 2026; going-concern doubt and expected future losses disclosed

Risk Factors

  • No risk-factors section provided in the submitted excerpt
  • No disclosed new, updated, regulatory, operational, competitive, or financial risks in the available text

AI summary of the INMB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Sep 14, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Board expanded to seven directors with additions of R. Duane Clark II and James Sapirstein
  • Both appointees classified independent under Nasdaq Listing Rule 5605

Item 8.01: Other Events

  • Board appointments of Mr. Clark and Mr. Sapirstein announced September 14, 2026
  • Governance expansion potentially relevant to strategic oversight and shareholder confidence

Item EX-99.1: Item EX-99.1

  • Board appointments of R. Duane Clark II and James Sapirstein add rare-disease commercialization and biopharma transaction expertise
  • Clark’s Sanofi rare-disease leadership supports Ebstrocel™ market access, pricing, patient identification and launch planning
Filed Jul 31, 2026Full analysis →

Item 8.01: Other Events

  • Australia R&D cash rebate of approximately $4.2 million received July 30, 2026
  • Non-dilutive cash inflow supporting INmune Bio’s research and development funding

Item EX-99.1: Item EX-99.1

  • Approximately $4.6M in non-dilutive R&D rebates received from Australia and the UK during June–July 2026
  • Australia rebate approximately $4.2M received July 30, 2026; UK rebate approximately $0.4M received during June
Filed Jul 1, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • Warrant exercise price cut to $1.40 from $1.95 for 647,112 warrants
  • Expected gross proceeds of $905,957 from cash exercises

AI summaries of INMB 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for INMB

Don't miss the next INMB filing

  • Alerts as it files. A push when INMB files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut INMB, by share count.
  • Ask anything. An AI agent that reads every INMB filing and answers with sources.
Follow INMB for alertsAsk AI about INMB
Compare plans →

INMB alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
SAPIRSTEIN JAMESASep 15, 2026-
Clark Ronnie DuaneASep 15, 2026-
Juda ScottMJul 2, 2026$1.40
Juda ScottXJul 2, 2026$0.13
Lowdell Mark WilliamMJul 2, 2026$1.40
Lowdell Mark WilliamXJul 2, 2026$0.13
Moss David JMJul 2, 2026$1.40
Moss David JXJul 2, 2026$0.13
Insider trades across all companies →Which insider buys matter →

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$155K$14K$50K
Operating Income--$42.6M-$47.4M
Net Income-$30.0M-$42.1M-$45.9M
Op. Margin--304535.7%-94766.0%
Net Margin-19360.0%-300585.7%-91866.0%
Balance Sheet
Total Assets$57.0M$39.6M$32.4M
Equity-$32.1M$23.5M
ROE--131.1%-195.3%
Per Share
EPS$-1.67$-2.11$-1.86
Cash Flow
Operating CF-$12.0M-$33.4M-$22.6M
CapEx--$1.0M

Source: XBRL data in Inmune Bio, Inc. (INMB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q2 2026

Aggregate INMB share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
INMB shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q2 202620$4.3M
Q1 202618$3.9M
Q4 202517$5.2M
Q3 202517$7.3M
Q2 202518$9.5M
Q1 202515$17.7M
Q4 202412$10.8M
Q3 20249$4.5M
Position changes: Q1 2026 → Q2 2026
Top Sellers

Source: 13F-HR filings on SEC EDGAR (aggregated from 126 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

INMB filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

10-K annual reports

10-Q quarterly reports

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Sep 23, 2026--
4Sep 17, 2026--
8-KSep 14, 2026Analysis-
10-QAug 6, 2026Analysis
8-KJul 31, 2026Analysis-
4Jul 7, 2026--
4Jul 7, 2026--
4Jul 7, 2026--
8-KJul 1, 2026Analysis-
8-KJun 23, 2026Analysis-
8-KJun 17, 2026Analysis-
8-KJun 2, 2026Analysis
8-KMay 14, 2026Analysis
10-QMay 7, 2026Analysis
8-KMay 5, 2026Analysis-
10-KMar 30, 2026-
8-KFeb 27, 2026Analysis-
8-KFeb 23, 2026Analysis-
8-KFeb 19, 2026-
8-KFeb 13, 2026-
8-KJan 27, 2026-
8-KDec 23, 2025-
8-KDec 19, 2025-
8-KDec 10, 2025-
8-KDec 8, 2025-

Related Health Care companies

All Health Care →

INMB SEC filings: frequently asked questions

Which institutions hold INMB stock?

As of June 30, 2026, the largest Inmune Bio, Inc. (INMB) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($1.2 million), AQR Capital Management ($1.1 million), BlackRock ($508,000), Raymond James Financial ($347,000), Goldman Sachs Group ($302,000). 13F-HR reports are filed up to 45 days after each quarter ends.

What was INMB's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Inmune Bio, Inc. (INMB) reported revenue of $50,000 (up 257.1% from FY2024) and a net loss of $45.9 million. Diluted EPS was -$1.86. The figures come from the XBRL data in the 10-K.

What did INMB report in its latest 8-K?

Inmune Bio, Inc. (INMB) filed an 8-K on September 14, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers) and Item 8.01 (Other Events). Board expanded to seven directors with additions of R. Duane Clark II and James Sapirstein.

What are the latest INMB SEC filings?

Inmune Bio, Inc. (INMB) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 14, 2026 and a Form 4 insider filing on September 23, 2026.

What is INMB's SEC CIK number?

Inmune Bio, Inc. (INMB)'s SEC Central Index Key (CIK) is 1711754. EDGAR lists every INMB filing under that number.

Ask anything about INMB

The research agent reads INMB's filings, financials, insider trades and 13F holders, then answers with sources.

Start free